NGM

Non-genetically modified cell therapies are commonly used in the treatment of oncology and rare diseases. 64% of these therapies are being developed for non-oncology rare diseases, while the remaining percentage is focused on oncology. The graph shows the pipeline development for each therapy based on indications. Non-genetically modified cell therapies are the most common therapeutic areas targeted. Of those therapies, oncology and rare diseases were the top areas of development. Of the non-genetically modified cell therapies, 64% were in development for non-oncology rare diseases, as seen in the graph, which is located red for non-oncology, otherwise known as rare diseases, and the purple for oncology. The graph on the side indicates figures based on indications in pipeline development for each therapy.